Testing insulin/GLP-1 combo with CGM for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This study tests a combination insulin/GLP-1 medicine (iGlarLixi) with continuous glucose monitoring to see how well it controls blood sugar in Chinese adults with type 2 diabetes. It may help those whose current pills are not working enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes for at least 1 year.
- You are currently taking metformin, either alone or with one other diabetes pill.
- Your blood sugar is not well controlled on your current medications.
- Your body mass index (BMI) is between 20 and 40.
- You are willing to wear a continuous glucose monitor (CGM) and check your blood sugar at home.
- You are willing to stop taking certain diabetes pills (like sulfonylureas, glinides, alpha-GI, or DPP-4 inhibitors) for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new injection that combines insulin with liraglutide works better than standard premixed insulin for people with type 2 diabetes. It aims to improve blood sugar control and simplify treatment.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This study tests an experimental medicine called RGB-5088 for people with type 2 diabetes who are already using insulin. The goal is to see if it can safely improve blood sugar control when added to your current diabetes management.
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
Hear when a new Type 2 Diabetes (T2D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.